Spinal meningiomas arise from arachnoid cap cells (meningothelial cells) of the spinal meninges. They are among the most common primary intradural extramedullary tumors of the spinal canal and account for approximately one quarter of spinal tumors.
According to the WHO Classification of Tumours of the Central Nervous System, meningiomas are assigned to three histopathological grades:
Spinal meningiomas typically grow slowly and may therefore remain clinically silent for a prolonged period. Neurological symptoms develop primarily as a consequence of progressive compression of the spinal cord and, less commonly, adjacent nerve roots.
Computed tomography is particularly useful for demonstrating intratumoral calcification and assessing associated osseous anatomy.
CT myelography may serve as an alternative in patients in whom MRI is contraindicated or cannot be performed.
Definitive histopathological diagnosis is generally obtained following surgical resection or biopsy. There are no specific circulating tumor markers for spinal meningioma.
Management of spinal meningioma is individualized according to neurological symptoms, tumor size, anatomical location, growth behavior, WHO grade, patient age, comorbidities, and previous treatment. Depending on the clinical situation, the following strategies may be used alone or in combination.
Stereotactic radiosurgery and stereotactic radiotherapy have an increasingly established role in the management of selected spinal meningiomas, particularly for residual disease following subtotal resection and for recurrent tumors.
The high spatial precision of the CyberKnife system allows highly conformal treatment of lesions in challenging anatomical locations, including ventral or ventrolateral tumors in close proximity to the spinal cord, while rigorously limiting radiation exposure to the spinal cord and adjacent neural structures.
CyberKnife uses robotically guided, non-isocentric, multi-directional beam delivery to achieve highly conformal dose distributions tailored to the three-dimensional geometry of the meningioma. Target-volume delineation is based on high-resolution contrast-enhanced MRI and planning CT. Dural involvement, including a radiographically evident dural tail where clinically appropriate, is assessed individually during treatment planning. Critical structures—most importantly the spinal cord, nerve roots, and other adjacent neural tissues—are precisely contoured, and established dose constraints are rigorously respected.
No. Small, asymptomatic spinal meningiomas without significant spinal cord compression may initially be managed with serial MRI surveillance. Treatment becomes appropriate when radiographic growth, progressive myelopathy, or other neurological symptoms develop. In patients with an increased operative risk or surgically challenging anatomy, stereotactic radiosurgery or radiotherapy may provide an effective non-invasive treatment alternative in appropriately selected cases.
Both arise from meningothelial cells, but they differ in anatomical location, clinical presentation, and therapeutic approach. Spinal meningiomas occur predominantly in the thoracic spine, show a particularly marked female predominance, and typically present with symptoms of progressive spinal cord compression and myelopathy. Intracranial meningiomas arise along the cranial dura—for example at the skull base or cerebral convexity—and may present with headache, seizures, cranial neuropathies, or focal neurological deficits depending on their location.
Yes. Recurrent spinal meningioma after surgery may be treated with CyberKnife® stereotactic radiotherapy without the need for repeat open surgery in appropriately selected patients. Re-irradiation after previous radiotherapy may also be feasible in selected cases, but requires meticulous reconstruction of the previous dose distribution and strict consideration of the cumulative spinal cord dose and other organ-at-risk constraints. Such decisions are made individually within the multidisciplinary tumor board.
Spinal meningiomas occur approximately three to four times more frequently in women than in men. Hormonal influences are considered biologically relevant because many meningiomas express progesterone receptors and, less consistently, estrogen receptors. Associations with exogenous hormonal exposure and pregnancy have been investigated, although the clinical significance varies according to tumor biology and individual circumstances.
Following complete microsurgical resection of a WHO grade 1 spinal meningioma, long-term recurrence rates are generally low. The risk increases when only subtotal resection is feasible, particularly in tumors with a ventral attachment, extensive dural involvement, or adherence to critical neural structures. WHO grade 2 meningiomas have a higher intrinsic recurrence risk. In selected patients with residual or recurrent disease, postoperative stereotactic radiosurgery or radiotherapy may improve durable local tumor control.
Whether a spinal meningioma requires treatment in an individual patient is determined at the ERCM following careful review of the clinical and imaging findings and a detailed personal consultation. Treatment decisions are made jointly with the multidisciplinary team and the patient.
We consider it essential that patients, their families, and those supporting them understand the nature of the condition, the available treatment options, the expected benefits, and the potential risks. Together with our medical partners, our team provides individualized guidance throughout the treatment pathway.
For treatment enquiries, please use our contact form. You may also contact us by telephone during our opening hours or via our social media channels.
Each enquiry is reviewed individually and processed promptly.